Washington Post Publisher Will Lewis Steps Down After Layoffs 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
 - EconoTimes)
NEW YORK, Sept. 08, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Medivation, Inc. (“Medivation” or the “Company”) (Nasdaq:MDVN) in the United States District Court for the Northern District of California on behalf of current stock holders of Medivation, seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the $81.50 per share merger consideration via a tender offer by Montreal, Inc., a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”), which was commenced on August 30, 2016 and is scheduled to expire on September 27, 2016 fails to provide Medivation shareholders with fair value for their shares. The Complaint also alleges that the inadequate merger consideration is the result of a rushed sale process during which the Board of Directors of Medivation caved to pressure from larger pharmaceutical companies that were eager to acquire Medivation at a discount to its intrinsic value and long-term prospects. Further, the Complaint alleges that in violation of Sections 14(e), 14(d)(4) and 20(a) of the Exchange Act, the tender offer documents omit certain material information, which renders the information disclosed materially misleading. Specifically, the Complaint alleges that the tender offer fails to disclose certain information about: (i) communications from other interested parties that were involved in negotiations to acquire Medivation; (ii) the terms of the confidentiality agreements entered into by such parties; and (iii) the valuation analyses performed by the Company’s financial advisors, J.P. Morgan Securities LLC (“J.P. Morgan”) and Evercore Group L.L.C. (“Evercore”).
If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
